Alembic Pharmaceuticals (APLLTD) Q4 23/24 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 23/24 earnings summary
1 Nov, 2026Executive summary
FY24 consolidated revenue from operations was ₹6,228.63 crore vs ₹5,652.62 crore; profit for the year was ₹615.82 crore vs ₹341.99 crore.
Q4 consolidated revenue was ₹1,516.98 crore vs ₹1,406.45 crore, and profit for the period was ₹178.21 crore vs ₹152.60 crore.
Standalone FY24 revenue was ₹5,874.06 crore vs ₹5,149.00 crore; profit was ₹666.48 crore vs ₹346.73 crore.
Financial highlights
Consolidated FY24 PBT was ₹631.83 crore vs ₹354.59 crore; EPS was ₹31.33 vs ₹17.40.
Consolidated Q4 EPS was ₹9.07 vs ₹7.76; total comprehensive income was ₹166.70 crore vs ₹151.42 crore.
Standalone Q4 revenue was ₹1,474.55 crore vs ₹1,307.12 crore; profit was ₹201.87 crore vs ₹130.54 crore.
Outlook and guidance
Sikkim manufacturing operations, disrupted by October 2023 flash floods, fully resumed in February 2024.
Latest events from Alembic Pharmaceuticals
- Q2 revenue grew 36% as margin expanded; FY27 growth guidance rose to 20%-25%.APLLTD
Q2 26/27 - Demerger-year PAT reached Rs 85.39 crore as export formulations grew 70%.APLLTDQ4 10/11
- FY12 growth strengthened across formulations and exports, led by API exports up 55%.APLLTDQ4 11/12
- Profit grew faster than revenue as specialty products and global expansion advanced.APLLTDQ4 12/13
- FY14 profit rose 43% as regulated-market growth lifted returns and funded expansion.APLLTDQ4 13/14
- FY15 growth and wider margins backed a major investment-led push into new markets.APLLTDQ4 14/15
- US-led growth more than doubled profit as R&D and capacity investment accelerated.APLLTDQ4 15/16
- Earnings reset after a one-off US launch as investment accelerates toward complex generics and growth.APLLTDQ4 16/17
- Profit rose as investment built US reach, R&D depth and manufacturing capacity.APLLTDQ4 17/18